ClinicalTrials.gg
Not yet recruitingNCT07937605Updated Nov 16, 2026

KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer

A Phase 2 interventional study of KC1086 and Fulvestrant in HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
29th of 94
168 · median 71
Started
2026
with 2 others
Phase 2
59 of 95
8 open now
Primary completion
2029-11
later than 21 of 22 live
Registered
95th of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 29th largest by planned enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2026, is one of 59 in phase 2, reaches primary completion later than 21 of the 22 other live ones, and was the 95th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of KC1086 in combination with fulvestrant in adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.

Read the detailed description

This multicenter study includes a Part 1 dose-escalation phase and a Part 2 randomized controlled phase.

Part 1 uses a single-arm dose-escalation design to evaluate the safety of KC1086 at 1 mg, 2 mg, or 4 mg once daily plus fulvestrant in participants with HR+/HER2- locally advanced or metastatic breast cancer.

Part 2 uses a randomized controlled design to evaluate the efficacy and safety of KC1086 at different dose levels plus fulvestrant in participants with HR+/HER2- locally advanced or metastatic breast cancer whose disease progressed after a CDK4/6 inhibitor, and to recommend the dose for a phase III study. Participants are stratified by endocrine resistance (primary versus secondary) and randomized 2:2:1 to low-dose KC1086 plus fulvestrant, high-dose KC1086 plus fulvestrant, or everolimus plus fulvestrant or exemestane. Treatment is given in 4-week cycles until disease progression, death, intolerable toxicity, or another protocol-specified reason for discontinuation.

03

Conditions studied

  • HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • Hormone receptor-positive
  • HER2-negative
  • KAT6 inhibitor
  • Breast cancer
  • KC1086
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed recurrent locally advanced (unresectable) or breast cancer that is hormone receptor-positive and -negative.
  2. Prior treatment with a CDK4/6 inhibitor.
  3. For Part 2 only: no more than 2 lines of prior systemic anticancer therapy for locally advanced (unresectable) or metastatic breast cancer.
  4. At least one as defined by 1.1, or non-measurable bone-only disease.
  5. (ECOG) performance status of 0 or 1.
  6. > 12 weeks.
  7. Adequate bone marrow, renal, and hepatic function.
  8. Patients should participate in the study voluntarily and sign .

Exclusion criteria

Exclusion Criteria:

  1. Known active uncontrolled or symptomatic central nervous system , carcinomatous meningitis, symptomatic , cerebral edema, and/or progressive growth of tumor.
  2. Another within the past 5 years, or a concurrent other malignancy.
  3. Inability to swallow or absorb oral medication, or gastrointestinal disease that interferes with drug absorption.
  4. Cardiovascular and cerebrovascular diseases.
  5. Any of the following before the first dose of study treatment:

    1. another drug within 4 weeks.
    2. immunotherapy, surgery, or radiotherapy within 4 weeks.
    3. a small-molecule targeted agent within 2 weeks or 5 half-lives, whichever is longer.
    4. cytotoxic chemotherapy within 3 weeks or 5 half-lives, whichever is longer.
    5. endocrine therapy within 2 weeks.
  6. Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to 6.0 Grade 0 or 1.
  7. Serious infection of CTCAE grade greater than 2 within 4 weeks before enrollment.
  8. Visceral crisis or organ failure for which chemotherapy, including an antibody-drug conjugate, is needed immediately, or which poses an immediate risk of a life-threatening complication; a large uncontrolled effusion; pulmonary lymphangitis; or hepatic involvement greater than 50%.
  9. Uncontrolled massive ascites, pleural or pericardial effusion.
  10. Prior treatment with everolimus(for Part 2 only ), or a known BRCA mutation.
  11. to any study drug or to any ingredient or of a study drug.
  12. Pregnant or lactating women.
  13. Female subjects of and male subjects of reproductive capacity who do not agree to use measures during the study and for 6 months after the end of the study.
  14. Other patients are not eligible for enrollment assessed by investigators.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Part1

    This is a single-arm dose-escalation phase. Participants will receive one of three KC1086 doses (1 mg, 2 mg, or 4 mg once daily) in combination with a fixed dose of fulvestrant.

    Drug: KC1086 · Drug: Fulvestrant

  • Experimental
    Part2

    This is a randomized controlled phase. Participants will be randomized in a 2:2:1 ratio to receive low-dose KC1086 plus fulvestrant, high-dose KC1086 plus fulvestrant, or everolimus plus fulvestrant or exemestane.

    Drug: Fulvestrant · Drug: Everolimus (10 mg QD) · Drug: Exemestane · Drug: KC1086

Interventions

  • DrugKC1086

    Dosage: 1 mg, 2 mg, or 4 mg; Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.

  • Dose: 500 mg. Route: intramuscular injection. Frequency: on Day 1 and Day 15 of Cycle 1, then on Day 1 of each cycle from Cycle 2 onward, 28 days as a cycle.

  • Dose: 10 mg. Route: oral, with or without food. Frequency: once daily, 28 days as a cycle.

  • Dose: 25 mg. Route: oral, after a meal. Frequency: once daily, 28 days as a cycle.

  • DrugKC1086

    Dosage: based on the doses selected in Part 1 (high dose and low dose); Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS in Part 1 is defined as the time from the first dose of study treatment to disease progression as assessed by RECIST 1.1 or death from any cause, whichever occurs first. PFS in Part 2 is defined as the time from randomization to disease progression as assessed by RECIST 1.1 or death from any cause, whichever occurs first.

    Time frame: Baseline to study completion (approximately 48 months)

  2. Adverse events (AEs)

    Assessed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the treatment assessed by NCI CTCAE 6.0.

    Time frame: Baseline to study completion (approximately 48 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed by RECIST 1.1.

    Time frame: Baseline to study completion (approximately 48 months)

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by RECIST 1.1.

    Time frame: Baseline to study completion (approximately 48 months)

  3. Duration of Response (DOR)

    DOR is defined as the time from the first documented PR or CR to the first documented progressive disease (PD) or death from any cause, whichever occurs first, as assessed by RECIST 1.1. DOR will be analyzed only in participants who achieve an objective response.

    Time frame: Baseline to study completion (approximately 48 months)

  4. Time to Response (TTR)

    TTR is defined as the time from the first dose of study treatment to the first documented CR or PR. TTR will be analyzed only in participants who achieve an objective response.

    Time frame: Baseline to study completion (approximately 48 months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937605
Lead sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2030 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion